Abogen has been invited to speak at the 5th LNP Formulation & Process Development Summit, taking place from April 6–8 2026, in Boston, MA. 

Dr. Bo Ying, CEO of Abogen, will join the forum of global industry leaders to exchange insights on cutting-edge advancements in LNP formulation, analytical characterization, and process development. He will share how AI-driven ionizable lipid design and improved in vitro-to-in vivo translation can accelerate the development of safer, more effective LNP-mediated theraputics.

Abogen’s Speaking Sessions:

Session 1: Fireside Chat

Topic: Bridging In Vitro/In Vivo Translation by Overcoming Limitations of Potency Assays & Animal Models to Accelerate Clinical Progress

Date & Time: April 7, 2026 – 1:30 PM (EDT)

Highlights:

① What key factors should guide the selection of cell lines to develop bioassays that best predict in vivo LNP potency?

② How to design quantitative assays that measure relevant payload expression levels for understanding biological activity?

③ Which animal models provide the most reliable assessment of LNP potency and how to better address variability in biodistribution and protein corona formation between species?

Session 2: Keynote Presentation

Topic: An “Irrational” Ionizable Lipid Design Approach Based on Machine Learning Models

Date & Time: April 7, 2026 – 3:30 PM (EDT)

Highlights:

① Conventional ionizable lipid design approach is based on SAR model, innovative ionizable lipid structures are limited, SM-102 and Lipid-5 are still the benchmark for mRNA delivery.

② Abogen has established a library of ionizable lipids with in vivo test results to train our in-house machine learning model and as the model matures, we have gradually switched from rational design to AI-driven ionizable lipid generation approach.

③ The AI-driven lipid generator has created some truly innovative structures that demonstrated superior properties not only in efficiency and safety, it may help to overcome certain limitations in LNPs during repeated i.v. dosing.